Statin-associated muscle symptoms: epidemiology, risk factors, mechanisms and treatment

Statins are widely prescribed and the risk of adverse drug reactions of lipid-lowering therapy is actively discussed, including muscle symptoms. This review synthesizes the knowledge about the clinical aspects of statin-associated muscle symptoms, which is important for the practitioner. Potential mechanisms of their development, risk factors, clinical manifestations, treatment and prevention are described. Timely detection the side effects of statins makes it possible to diagnose and eliminate, which is crucial for conducting lipid-lowering therapy for patients with atherosclerotic cardiovascular diseases. Management of statin-associated muscle symptoms requires altering (reduced dosages, use of another statin or alternative lipid-lowering drugs) or discontinuing the statin treatment. 

1. Koziolova N.A. Combined lipid-lowering therapy: choosing strategy and tactics. Cardiovascular Therapy and Prevention. 2010;9(4):107–15. [Russian]

2. Eganyan R.A. Statins in the primary prevention of coronary heart disease (a review). Preventive Medicine. 2013;16(3):37–43. [Russian]

3. Mansi I, Frei CR, Pugh MJ, Makris U, Mortensen EM. Statins and Musculoskeletal Conditions, Arthropathies, and Injuries. JAMA Internal Medicine. 2013;173(14):1–10. DOI: 10.1001/jamainternmed.2013.6184

4. Ezhov M.V., Sergienko I.V., Aronov D.M., Arabidze G.G., Akhmedzhanov N.M., Bazhan S.S. et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations VI revision. Atherosclerosis and Dyslipidemias. 2017;3:5–22. [Russian]

5. Aronov D.M., Arabidze G.G., Akhmedzhanov N.M., Balakhonova T.V., Boytsov S.A., Bubnova M.G. et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations. V revision. 2012;1–50. [Russian] https://scardio.ru/content/Guidelines/rek_lipid_2012.pdf

6. Boytsov S.A., Pogosova N.V., Bubnova M.G., Drapkina O.M., Gavrilova N.E., Yeganyan R.A. et al. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;23 (6):7–122. [Russian]. DOI: 10.15829/1560-4071-2018-6-7-122

7. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37(39):2999–3058. DOI: 10.1093/eurheartj/ehw272

8. NICE guideline. Cardiovascular disease: risk assessment and reduction, including lipid modification. (CG181). 2014;1–44. [Av at: https://www.nice.org.uk/guidance/cg181/resources/cardiovascular-disease-risk-assessment-and-reduction-including-lipid-modification-35109807660997]

9. NICE clinical guideline. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2014;1–55. [Av at: https://depts.washington.edu/uwmedres/pdf/immersion/UK%20NICE%20guidelines%202014.pdf]

10. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S1–45. DOI: 10.1161/01.cir.0000437738.63853.7a

11. Parish E, Bloom T, Godlee F. Statins for people at low risk. BMJ. 2015;351:h3908. DOI: 10.1136/bmj.h3908

12. Schwitzer G. Statins, news, and nuance. BMJ. 2016;353:i3379. DOI: 10.1136/bmj.i3379

13. Diamond D, Kendrick M, Mascitelli L. Exaggerated report of benefits in a flawed long term statin treatment study. BMJ. 2017;359:j4915. DOI: 10.1136/bmj.j4915

14. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347(oct22 3):f6123–f6123. DOI: 10.1136/bmj.f6123

15. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L et al. Interpretation of the evidence for the efficacy and safety of statin therapy. The Lancet. 2016;388(10059):2532–61. DOI: 10.1016/S0140-6736(16)31357-5

16. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: A common dilemma not reflected in clinical trials. Cleveland Clinic Journal of Medicine. 2011;78(6):393–403. DOI: 10.3949/ccjm.78a.10073

17. Napalkov D.A. The safety of statins: what a physician needs to know. Rational Pharmacotherapy in Cardiology. 2014;10(3):334–8. [Russian]

18. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. Journal of the American College of Cardiology. 2016;67(20):2395–410. DOI: 10.1016/j.jacc.2016.02.071

19. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K et al. Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science. 2015;11(1):1–23. DOI: 10.5114/aoms.2015.49807

20. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK et al. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal. 2015;36(17):1012–22. DOI: 10.1093/eurheartj/ehv043

21. Guyton JR, Bays HE, Grundy SM, Jacobson TA. An assessment by the Statin Intolerance Panel: 2014 update. Journal of Clinical Lipidology. 2014;8(3):S72–81. DOI: 10.1016/j.jacl.2014.03.002

22. Diamond DM, Ravnskov U. How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Expert Review of Clinical Pharmacology. 2015;8(2):201–10. DOI: 10.1586/17512433.2015.1012494

23. Rumyantsev N.A., Kukes V.G., Kazakov R.E., Rumyantsev A.A., Sychev D.A. Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy. Therapeutic Archive. 2017;89(1):82–7. [Russian]. DOI: 10.17116/terarkh201789182-87

24. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews. 2017;2:MR000033. DOI: 10.1002/14651858.MR000033.pub3

25. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the Statin Muscle Safety Task Force: 2014 update. Journal of Clinical Lipidology. 2014;8(3):S58–71. DOI: 10.1016/j.jacl.2014.03.004

26. Kobalava Zh.D., Villevalde S.V., Shavarova E.K. Statin safety: myths and reality. Cardiovascular Therapy and Prevention. 2007;6(2):105–12. [Russian]

27. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study. Cardiovascular Drugs and Therapy. 2005;19(6):403–14. DOI: 10.1007/s10557-0055686-z

28. Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of Musculoskeletal Pain and Statin Use. Journal of General Internal Medicine. 2008;23(8):1182–6. DOI: 10.1007/s11606-0080636-7

29. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. Journal of Clinical Lipidology. 2012;6(3):208–15. DOI: 10.1016/j. jacl.2012.03.003 3

30. / Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J et al. Effect of Statins on Skeletal Muscle Function. Circulation. 2013;127(1): 96–103. DOI: 10.1161/CIRCULATIONAHA.112.136101

31. Spence JD, Dresser GK. Overcoming Challenges With Statin Therapy. Journal of the American Heart Association. 2016;5(1):e002497. DOI: 10.1161/JAHA.115.002497

32. Graham DJ. Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs. JAMA. 2004;292(21):2585–90. DOI: 10.1001/jama.292.21.2585

33. Drapkina O.M., Chernova E.M. Myopathy as a side effect of statin therapy: mechanisms of development and prospects for treatment. Rational Pharmacotherapy in Cardiology. 2015;11(1):96–101. [Russian]

34. Rizos CV, Elisaf MS. Statin myopathy: navigating the maze. Current Medical Research and Opinion. 2017;33(2):327–9. DOI: 10.1080/03007995.2016.1255601

35. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. European Journal of Preventive Cardiology. 2014;21(4):464–74. DOI: 10.1177/2047487314525531

36. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. The Lancet. 2017;389(10088):2473–81. DOI: 10.1016/S0140-6736(17)31075-9

37. Pedro-Botet J, Rubiés-Prat J. Statin-associated muscle symptoms: beware of the nocebo effect. The Lancet. 2017;389(10088):2445–6. DOI: 10.1016/S0140-6736(17)31163-7

38. Vladutiu GD. Genetic predisposition to statin myopathy. Current Opinion in Rheumatology. 2008;20(6):648–55. DOI: 10.1097/BOR.0b013e328314b7b4

39. Kazakov R.E., Evteev V.A. Significance of genetic factors in predicting the side effects of statins. International journal of applied and fundamental research. 2016;8–5:691–8. [Russian]

40. Grigoricheva E.A., Evdokimov V.V. Pharmacogenetic methods in evaluation of statin therapy complications risk. Continuing medical education and science. 2016;11(1):32–5. [Russian]

41. Khokhlov A.A., Sychev D.A. Evaluation of the frequency of potentially significant drug-drug interactions in patients taking statins. Clinical Pharmacology and Therapeutics. 2015;24(5):38–42. [Russian]

42. Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions with Statins and Select Agents Used in Patients with Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016;134(21):e468–95. DOI: 10.1161/CIR.0000000000000456

43. Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. British Journal of Clinical Pharmacology. 2004;57(4):525–8. DOI: 10.1111/j.1365-2125.2003.02044.x

44. Mammen AL. Statin-Associated Autoimmune Myopathy. New England Journal of Medicine. 2016;374(7):664–9. DOI: 10.1056/NEJMra1515161